Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)

NCT07118670 is registered in ClinicalTrials.gov with Edward Wood, MD as lead sponsor.

NCT NCT07118670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07118670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)
Lead sponsor
Edward Wood, MD
Phase
Phase 4
Overall status
Active, not recruiting
Start date
December 8, 2025
Completion date
April 30, 2028
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

proliferative diabetic retinopathy (pdr)